Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 May 15;10(10):1466-70.
doi: 10.3748/wjg.v10.i10.1466.

Overexpression of annexin 1 in pancreatic cancer and its clinical significance

Xiao-Feng Bai  1 , Xiao-Guang Ni, Ping Zhao, Shang-Mei Liu, Hui-Xin Wang, Bing Guo, Lan-Ping Zhou, Fang Liu, Jin-Sheng Zhang, Kun Wang, Yong-Qiang Xie, Yong-Fu Shao, Xiao-Hang Zhao
Affiliations

Overexpression of annexin 1 in pancreatic cancer and its clinical significance

Xiao-Feng Bai et al. World J Gastroenterol. .

Abstract

Aim: To investigate the expression of annexin I in pancreatic cancer and its relationship with the clinicopathologic factors, and to evaluate its potential clinical significance.

Methods: Annexin I expression was analyzed by Western blot and immunohistochemical staining in pancreatic adenocarcinoma and multi-tissue microarrays (MTAs).

Results: Western blot analysis showed that annexin I was overexpressed in 84.6% (11/13) pancreatic ductal adenocarcinomas. Immunohistochemistry analysis of pancreatic cancer in MTAs showed that annexin I protein was 71.4%(30/42) positive which was markedly increased compared with that in the tumor matched normal pancreas tissues 18.4%(7/38) (P<0.01). In the meantime, the high expression of annexin 1 was correlated with the poor differentiation of pancreatic adenocarcinoma.

Conclusion: Annexin 1 overexpression is a frequent biological marker and correlates with the differentiation of pancreatic cancer during tumorigenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Western blot analysis of annexin I in pancreatic duc-tal adenocarcinoma. Ten micrograms of total protein extracts from pancreatic tissues and cell lines were run on 120 g/L SDS-PAGE, and annexin I protein expression was probed with mouse anti-annexin I monoclonal antibody and visualized by chemiluminescence (top panel). C: pancreatic ductal adenocar-cinoma tissues; N: normal pancreas tissues; BxPC-3: human pancreatic adenocarcinoma cell line. α-Tubulin was used as an internal control (bottom panel).
Figure 2
Figure 2
Immunohistochemical analysis of annexin I expression on pancreatic cancer MTAs. A and B: Overview of the H & E staining and immunohistochemical staining of annexin I on pancreatic cancer MTAs; C (× 200) and D (× 400): normal pancreas; E (× 200) and F (× 400): well differentiated ductal adenocarcinoma; G (× 200) and H (× 400): poorly differentiated ductal adenocarcinoma.
See this image and copyright information in PMC

References

    1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26. - PubMed
    1. Wang L, Yang GH, Lu XH, Huang ZJ, Li H. Pancreatic cancer mortality in China (1991-2000) World J Gastroenterol. 2003;9:1819–1823. - PMC - PubMed
    1. Tan ZJ, Hu XG, Cao GS, Tang Y. Analysis of gene expression profile of pancreatic carcinoma using cDNA microarray. World J Gastroenterol. 2003;9:818–823. - PMC - PubMed
    1. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, Chan DW, Canto M, Lillemoe KD, Cameron JL, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868–1875. - PubMed
    1. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, Berg K, Hollingsworth MA, Cameron JL, et al. Discov-ery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239–1249. - PMC - PubMed

Publication types

MeSH terms